Fifty patients with primary epidermoid carcinomas of the nasal sinuses were treated by intra-arterial chemotherapy, alone (2 fatal iatrogenic accidents occurred) or in association with surgery and/or radiotherapy (48 cases). Adverse reactions due to chemotherapy were noted in 11 patients (22%), and two of these were fatal (4%). In eleven patients (22%) the initial curative chemotherapy was unsuccessful and all died after a mean survival period of 12 months. Local recurrence was observed in 7 patients (14%), the mean survival period being 11,5 months, and in 6 patients (12%) with local glandular involvement the mean period was 15 months. Identical survival rates of 57% after 3 years (8/14) and 50% after 5 years (6/12) were observed in 14 cases with endosinusal forms and 14 patients in whom the infrastructures were treated. In 22 patients there was exteriorization of the lesion, and the survival rate was 31% after 3 years (7/22) and 15% after 5 years (3/19). All 7 patients with pterygomaxillary lesions died within 3 years. Overall results in the 50 patients treated show that: -- 23/50 (46%) survived for 3 years -- 15/43 (35%) for 5 years -- 5/19 (26%) for 10 years.

Over the last 10 years 267 treatments with cervical cancer have been treated with chemotherapy in 4 anticancer centers. The analysis of these results shows: 1) 9 per cent of the treatments were discontinued because of clinical and hematological intolerance reactions; these intolerance reactions were responsible for 1 per cent of the therapeutic deaths; 2) an effect on the functional symptoms in 52 per cent of the patients with multiple drug regimens; 3) an objective global response in 18 per cent of the patients treated with single drug therapy (3 regressions greater than 50% out of 6 cases treated with cis-platinum) and in 22 per cent of the patients treated with various associations. Comparison of these results to recent data in the literature confirms: 1) the hope of improving objective results by developing more rational protocols of association, since, for the moment more active drugs are not available; 2) a much more marked chemotherapeutic action on lesions which have not been previously irradiated (statistically significant differences in response). Chemoresistance in cervical cancers may not be as frequent or as insurmountable as generally believed. The role of chemotherapy may be visualized from: 1) the palliative point of view, for efficacy while reducing toxicity); 2) induction sequence in curative treatment programs for advanced local forms with unfavorable prognosis (logical and attractive orientation of therapeutic studies); 3) the point of view of adjuvant treatment which remains to be defined. Rigorous studies are required to assess whether chemotherapy can give eventual long term improvement in high risk cervical cancers.

Toyocamycin (TMC), an adenosine analog, impairs qualitatively and quantitatively virus production in a cellular system chronically infected by Friend Virus. Viral particles released by cell cultures treated with 0.2 microgram/ml of the drug have lost most of their glycoprotein (gp 70) content. This phenomenon is likely to modify the viral envelope and could explain the loss of infectivity of the virus.

224 patients with stage III and IV Hodgkin's disease (H.D.) have been treated by 6 monthly MOPP courses. 190 patients achieved remission and among them there were 109 complete remissions (C.R.) . All patients received vinblastin maintenance combined with "reinduction" courses of MOPP (68 patients) or irradiation (57 patients). At ten years, remission curves are "on plateau" at 72% for those patients who achieved C.R. at 48% for those who had partial remission, and for all patients the ten years survival rate is 53%. The parameters which influence C.R. achievement are age, fever, histology, but the best predictive parameter seems to be lymphogram: diffuse involvement and aspects of cystic storage pattern as seen in "non Hodgkin lymphoma" heralding an unfavorable prognosis. The lymphogram picture should thus be included as parameter of initial classification and treatment active in "non Hodgkin lymphoma" such as Vincristine - Cytoxan - Prednisone - Adriamicin should be tried in these high risk patients.

Leg paralysis and wallerian degeneration of sciatic nerve fibres have been produced in rats by intraneural injection of 0.5, 1 or 5 microgram of vincristine (VCR) or formyl leurosine (FLR) dissolved in 5 microliter of saline. Nerve lesions were dose-related, and were similar for equal concentrations of the two drugs. Six patients received one to three 5-day courses of FLR. The total dose of FLR administered ranged from 15 to 131 mg (mean 83 mg). Clinical signs of peripheral neuropathy were absent in four patients, and limited to orthostatic hypotension in one case and transient depression of reflexes in another. Motor conduction velocities measured in four peripheral nerves, and muscle evoked potentials remained unchanged throughout the treatment in all patients.

11 patients experienced 40 intrathecal injections of cytotoxic drugs during the treatment of acute leukemia. Tiapride was used as a preventive or curative therapy for headache. Results were found excellent or good in 70% of cases. Frequency and intensity of headache were reduced by half. Tiapride seems more effective in early headache than in cephalalgia occuring later.

In our 98 patients all treated by association chemotherapy + cobaltherapy, 37 cases were stages III and IV and 71 cases were of diffuse pathology classification. Meanwhile the results were not so poor: 66% at 5 years survival (all stages) and 69% for stages I and II. The curves of survival rate generally stabilize at 7 years. The prognostic depend of the pathology class: diffuse LBS and diffuse HBS have an evolution similar to acute leukemia (44.5% and 19% at 7 years survival), on the opposite nodular LBS, diffuse LCS have 100% survival at 7 years. Diffuse cases have visceral relapses (liver, bone marrow, Waldeyer ring) or generalized lymphatic involvement; nodular cases have generally localized and only lymph-nodes relapses. The best results by large fields irradiation suggest a contiguous extension of the disease, but there is also distant lymph nodes relapses. In the nodular cases, relapses can be generally cured by localized radiotherapy. In the diffuse case, we do not know if it is better to give total lymphnode irradiation (or to give more chemotherapy with economic irradiation). 10 gastro-intestinal cases were treated by moving strip technique with excellent tolerance and 67.5% at 5 years survival. These results show that interesting results may be obtained in non Hodgkin lymphomas by association of chemotherapy, with selective and moderately large fields irradiation, even in disseminated cases, even in diffuse cases.